Ataciguat - Rancho Santa Fe Bio
Alternative Names: 1766; Ataciguat - RSF Bio; HMR 1766Latest Information Update: 28 Jul 2024
At a glance
- Originator sanofi-aventis
- Developer Rancho Santa Fe Bio
- Class Anthranilic acids; Benzamides; Cardiovascular therapies; Chlorobenzenes; Morpholines; Small molecules; Sulfonamides; Thiophenes
- Mechanism of Action Guanylate cyclase stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Unspecified
- No development reported Aortic valve stenosis
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for clinical-Phase-Unknown development in Aortic-valve-stenosis in USA (PO, Capsule)
- 23 Jun 2021 Ataciguat - Rancho Santa Fe Bio is available for licensing as of 23 Jun 2021. https://rsfbio.com/
- 23 Jun 2021 Discontinued - Phase-II for Neuropathic pain in Europe (PO)